This online on-demand 70-minute seminar gives a comprehensive understanding of the hospital reimbursement landscape for medical devices in England. Additional modules cover reimbursement of IVD tests, medical aids, and screening methods
Available as a pre-recorded webinar or full presentation in Acrobat PDF
England is one the most attractive markets for medical devices in Europe.
Large population, well-structured reimbursement processes and first-class research and treatment facilities make it the country of choice for market entry for medical device companies.
On the other side, market access in England is very much evidence-driven, which requires good level of clinical evidence for acceptance of novel technologies. Also, a complex reimbursement system (National Tariff Payment System) and funding framework (including commissioning by NHS England or Integrated Care Boards) with a strong advisory role of National Institute for Health and Care Excellence (NICE) makes the market access environment difficult to understand and navigate in.
We built this seminar based on experience from dozens of market access projects in England, to help develop better understanding of the market access landscape in England and to inform better business decisions whether to go to this market or not and if yes, how to approach it.
Key stakeholders are reviewed including payers, policy-makers, advising organizations, managers of procedural (OPCS) classification and payment system (HRG, National Tariff)
Specifics of commissioning processes by NHS England and Integrated Care Boards (ICBs) are reviewed as well
Money flow and distribution of funds, overview of the payment models (within and outside National Tariff Payment System), composition of National Tariff, specifics of Healthcare Resource Groups (HRGs), process to introduce changes into HRG system
Landscape after Accelerated Access Review, Accelerated Access Collaborative, transformative technologies, Innovation and Technology Payment, Commissioning through Evaluation
Overview of five med tech and IVD programs at NICE, role of HTA in market access for medical devices and IVD tests
A separate comprehensive overview of the reimbursement system for IVD tests in England
A separate comprehensive overview of the organizational and financing framework of screening methods (e.g. breast and cervical cancer screening) in England
A separate comprehensive overview of the reimbursement system for medical aids in England
Some topics are not specifically covered in this seminar: reimbursement model in out-patient settings, nuances of health technology assessments at NICE, funding of capital equipment
Introductory presentation also does not include details of reimbursement application processes (e.g. application form, requirements, details of the process for creation of procedure code, HRG change, adding device to the High Cost Device List etc.)
Topics that are not covered in this seminar, will be covered in the future courses. You can subscribe to our newsletter and inform us about your particular interests at the main page of the Market Access Academy
One option is to watch the seminar, which is provided as a pre-recorded webinar. The duration of the webinar is 1 hour 14 minutes. Seminar is available for 6 months
You can also access just the educational material - the full presentation of the seminar in Acrobat PDF
This 3-minute extract presents overview of the reimbursement via High Cost Device List in England
September 2022: Update of the overview of English hospital reimbursement system (Integrated Care Boards (ICBs) became fully operational and replaced Clinical Commissioning Groups (CCGs) from July 01, 2022; added information on expected changes in the payment system from April 2023; NHS Innovation Service will replace HealthTech Connect)
May 2022: Update of the overview of English hospital reimbursement system (introduced the Integrated Care Systems (ICS) as new local commissioning stakeholders, introduced Unified Tech Fund (UTF) as a mean that supports innovation, added a new slide for Evidence-based interventions program)
March 2022: Update of the overview of English reimbursement system for screening methods (Public Health England was dissolved in 2021. Its tasks regarding screening activities were divided between Department of Health and NHS England, introduced NHS Digital, which manages the information system used to select and invite individuals to participate in the screening programs, updated the graphical presentation of the integral overview of the pathway to introduce a population screening method in England)
May 2021: Substantial update of the overview of the English hospital reimbursement system (radical change of the payment system with the introduction of the 2021/22 aligned payment and incentive approach, Commissioning Through Evaluation and Innovation and Technology Payment programs were discontinued, introduction of the concept of the Integrated Care Systems and Sustainability and Transformation Partnerships, new information regarding MedTech Funding Mandate)
April 2021: Update of the overview of English IVD reimbursement system (new slide related to updating of the National Genomic Test Directory was added)
September 2020: Update of the overview of English IVD reimbursement system (introduced NHSX in the ‘Overview of key reimbursement stakeholders’ slide, introduced a slide with National Genomic Test Directory concept, updated the ‘Summary of innovative landscape in England’ slide, introduced slides explaining the MedTech Funding Mandate and Rapid Uptake Products)
April 2020: Substantial update of the overview of the English system: changes in the innovation funding landscape, updates related to Commissioning through Evaluation and Innovation and Technology Payment, Rapid Uptake Products and Pathway Transformation Fund, MedTech Funding Mandate, Device Working Groups and centralized procurement of the High Cost Device List products
December 2019: Update of the overview of English IVD reimbursement system (new slide with overview of reimbursement pathways, new slide on clinical and economic requirements for the Innovation Technology Payment scheme)